 |
|
Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
Seung-Hoon Lee, Sang Won Jeon, Cheolmin Shin, Chi-Un Pae, Ashwin A. Patkar, Prakash S. Masand, Hyonggin An, Changsu Han
Psychiatry Investig. 2022;19(4):268-280. Published online 2022 Apr 22 DOI: https://doi.org/10.30773/pi.2021.0368
|
|
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis
Isabella Berardelli, Elena Rogante, Federico Formica, Riccardo Iannazzo, Attilio Valerio Mammoliti, Raffaele Riccioni, Skender Veizi, Roger S McIntyre, Maurizio Pompili
Journal of Psychopharmacology.2025; 39(2): 92. CrossRef Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
Muriel Vicent-Gil, Joan Trujols, Teresa Sagués, Maria Serra-Blasco, Guillem Navarra-Ventura, Cecilia Lucía Mantellini, Sara Crivillés, Maria J. Portella, Narcís Cardoner
Annals of General Psychiatry.2025;[Epub] CrossRef The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature
Francesco Weiss, Bruno Pacciardi, Giulia D’Alessandro, Valerio Caruso, Icro Maremmani, Stefano Pini, Giulio Perugi
Journal of Clinical Medicine.2024; 13(2): 531. CrossRef Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database
Ying Jiang, Yusi Cheng, Zhiqiang Du, Yuan Shen, Qin Zhou, Yingying Ji, Haohao Zhu
Journal of Psychopharmacology.2024; 38(6): 567. CrossRef A Randomized Controlled Trial Comparing Efficacy and Safety of Antidepressant Monotherapy
N. Simple Santi, Sashi B Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo, Bhabagrahi Rath
Cureus.2024;[Epub] CrossRef Vortioxetine versus reuptake inhibitors in adults with major depressive disorder: A systematic review and meta-analysis of randomized controlled trials
Eduardo Cerchi Barbosa, Giovanna Hanike Santos da Silva, Ângelo Eduardo Espíndola Sbardelotto, Douglas Carneiro Barroso, Fernanda Ribeiro de Lima, Loyná Euá Flores E Paez, Saulo Bernardo Lança, Arthur Bezerra Cavalcanti Petrucci, Felipe Bandeira de Melo G
Asian Journal of Psychiatry.2024; 101: 104222. CrossRef An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
N Simple Santi, Sashi Bhusan Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo, Bhabagrahi Rath
Cureus.2023;[Epub] CrossRef Repercusión de vortioxetina sobre la función sexual frente a otros antidepresivos
F. Sánchez-Sánchez, B. Ponce-Buj, A.L. Montejo-González, Y. Sipán-Sarrión, A. Gimeno-Marqués, A. Merino-Gámez
Medicina de Familia. SEMERGEN.2023; 49(7): 101997. CrossRef Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper
Gaia Sampogna, Filippo Caraci, Claudia Carmassi, Bernardo Dell’Osso, Silvia Ferrari, Giovanni Martinotti, Gabriele Sani, Gianluca Serafini, Maria Salvina Signorelli, Andrea Fiorillo
Expert Opinion on Pharmacotherapy.2023; 24(14): 1511. CrossRef Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism—In Vitro Study
Matej Ľupták, Zdeněk Fišar, Jana Hroudová
International Journal of Molecular Sciences.2022; 23(22): 13824. CrossRef
|